HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company
Transforming the way heart disease is diagnosed and treated, HeartFlow's artificial intelligence-enabled software platform brings precision heart care to cardiology.
The HeartFlow Analysis is the first and only non-invasive tool to assist with the diagnosis, management and treatment of patients with heart disease, the most common type of cardiovascular disease which accounts for one in three deaths and $1 out of every $6 of U.S. healthcare spend1.
HeartFlow has demonstrated higher diagnostic accuracy compared to other non-invasive tests2 with an 83% reduction in unnecessary invasive angiograms, resulting in a significant reduction in the total cost of care3.
Merging with Longview Acq
